Physician profile
Patrick Eugene Nolan
NPI 1821002205
$5,138.85
in general payments reported to CMS, 2019-2025
19 companies · $961 in 2025
The $961 reported for 2025 was more than what 78% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $581 · 2020: $828 · 2021: $723 · 2022: $674 · 2023: $600 · 2024: $771 · 2025: $961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,321 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,320.78 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,873.66 | 2019-2025 | Dovato, Cabenuva, Rukobia |
| Insmed, INC. | $1,216.96 | 2019-2024 | Arikayce |
| Merck Sharp & Dohme LLC | $610.35 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Gilead Sciences, INC. | $252.36 | 2019-2025 | |
| Theratechnologies INC. | $242.22 | 2019-2025 | Egrifta, Trogarzo |
| Abbvie INC. | $218.65 | 2021-2025 | |
| Melinta Therapeutics, LLC | $200.19 | 2019-2025 | Rezzayo, Vabomere, Kimyrsa |
| Paratek Pharmaceuticals, INC. | $120.42 | 2021-2022 | |
| Shionogi INC | $84.53 | 2023-2025 | Fetroja |
| Tetraphase Pharmaceuticals, INC. | $63.30 | 2019 | |
| La Jolla Pharmaceutical Company | $36.53 | 2023-2024 | Xacduro, Xerava |
| Seqirus USA INC | $33.74 | 2025 | Fluad, Flucelvax |
| Aimmune Therapeutics, INC. | $33.41 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $32.41 | 2023 | Austedo |
| Pfizer INC. | $31.07 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Products, Lp | $29.99 | 2019 | |
| Allergan, INC. | $25.39 | 2020 | |
| Nabriva Therapeutics, Plc | $17.78 | 2020 | |
| Ferring Pharmaceuticals INC. | $15.89 | 2025 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Nolan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.